EU Committee Nod For Lilly's Ixekizumab In Psoriasis
This article was originally published in The Pink Sheet Daily
Executive Summary
Product, to be branded as Taltz, looks set to be approved for moderate to severe plaque psoriasis after review by Europe's CHMP, with a US decision date coming up shortly for the Cosentyx competitor.